Found: 6
Select item for more details and to access through your institution.
Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.
- Published in:
- Cardiovascular Diabetology, 2020, v. 19, n. 1, p. 1, doi. 10.1186/s12933-020-01046-z
- By:
- Publication type:
- Article
Cardiovascular disease (CVD) risk assessment of HIV medication regimens using hematopoietic CD34+ progenitor cells.
- Published in:
- Stem Cell Research & Therapy, 2022, v. 13, n. 1, p. 1, doi. 10.1186/s13287-022-02775-6
- By:
- Publication type:
- Article
Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.
- Published in:
- Cardiovascular Diabetology, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12933-021-01235-4
- By:
- Publication type:
- Article
Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy.
- Published in:
- Arthritis & Rheumatology, 2023, v. 75, n. 7, p. 1229, doi. 10.1002/art.42450
- By:
- Publication type:
- Article
757-P: Cardiometabolic Disease Risk Assessment of HIV Medication Regimens.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-757-P
- By:
- Publication type:
- Article
92-LB: Linagliptin Improves CD34+ Progenitor Cells and Urine Exosomes.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-92-LB
- By:
- Publication type:
- Article